A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Basal Cell Carcinoma (BCC) Clinical Trial

Official title:
A Phase 1 Multiple Ascending Dose Study of BMS-833923 in Subjects With Advanced or Metastatic Solid Tumors

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the safety of BMS-833923 (XL139) in patients with advanced or metastatic cancers and determine the recommended phase 2 dose range and schedule

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00670189
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Completed
Phase	Phase 1
Start date	July 2008
Completion date	May 2014

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02750033` - Intraoperative Margin Assessment During Mohs Surgery
Recruiting	`NCT01633515` - Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study	N/A
Completed	`NCT02144077` - Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy	Phase 3
Completed	`NCT01108094` - Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas	Phase 2